TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07363577: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

Sponsor: LB Pharmaceuticals Inc. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 456 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07363577 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07363577 Rescue Dossier →